The idiopathic inflammatory myositis market is set for significant growth driven by the introduction of new therapies such as dazukibart (PF 06823859), efgartigimod, SAPHNELO (anifrolumab), brepocitinib, and HIZENTRA, among others. Furthermore, the increasing number of cases, influenced…